Clinical Report: Cardiometabolic Index as a Prognostic Marker for Stroke Risk

Overview

The Cardiometabolic Index (CMI) has been identified as a superior prognostic biomarker for predicting major adverse cerebrovascular events (MACEs) in patients with acute ischemic stroke (AIS) following thrombolytic therapy. A high CMI value (≥0.80) correlates with an increased risk of MACEs, with systemic inflammation playing a mediating role in this association.

Background

Stroke is a leading cause of morbidity and mortality globally, with recurrent strokes significantly impacting patient outcomes and healthcare systems. Identifying effective biomarkers for predicting adverse cerebrovascular events post-thrombolysis is crucial for optimizing patient management and improving long-term outcomes. The CMI, which reflects metabolic and inflammatory status, may enhance risk stratification in AIS patients.

Data Highlights

Key Findings

• CMI is a reliable prognostic biomarker for predicting MACEs in AIS patients post-thrombolysis.
• A high CMI value (≥0.80) is associated with an increased risk of adverse cerebrovascular events.
• Systemic inflammation partially mediates the relationship between CMI and adverse clinical outcomes.
• CMI provides better predictive capability compared to conventional biomarkers.
• Further large-sample cohort studies are needed to validate the clinical applicability of CMI.

Clinical Implications

The CMI can be utilized to refine risk stratification and inform individualized treatment strategies for AIS patients. Understanding the role of systemic inflammation in this context may guide therapeutic interventions aimed at improving patient outcomes.

Conclusion

The Cardiometabolic Index presents a promising tool for predicting recurrent stroke risk in patients with acute ischemic stroke, warranting further investigation to confirm its clinical utility.

Related Resources & Content

1. Frontiers in Neurology, 2026 -- Cardiometabolic index and modified cardiometabolic index are associated with early neurological deterioration in patients with acute ischemic stroke
2. Frontiers in Cardiovascular Medicine, 2026 -- The association between the C-reactive protein-triglyceride glucose index and myocardial injury after acute ischemic stroke: a machine learning analysis of the brain-heart axis
3. Frontiers in Cardiovascular Medicine, 2026 -- Prognostic value of CTI for major adverse cardiovascular events in patients With ST-elevation myocardial infarction after primary percutaneous coronary intervention
4. Guideline European Stroke Organisation (ESO) Guidelines on antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation
5. American College of Cardiology -- American and European Guideline Comparison for Ischemic Stroke and TIA: Key Points
6. Frontiers in Cardiovascular Medicine — The influence of C-reactive protein-triglyceride-glucose index (CTI) on the prognosis of heart failure patients with different ejection fractions
7. Frontiers | Cardiometabolic Index: A Novel Prognostic Biomarker for Recurrent Stroke Risk in Acute Ischemic Stroke Patients
8. Guideline European Stroke Organisation (ESO) Guidelines on antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation
9. Guideline European Stroke Organisation (ESO) expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA
10. American and European Guideline Comparison for Ischemic Stroke and TIA: Key Points - American College of Cardiology
11. Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
12. Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke - American College of Cardiology
13. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA - PubMed
14. Treat Stroke to Target - American College of Cardiology
15. Insulin Resistance Intervention After Stroke - American College of Cardiology
16. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial - PMC
17. OCEANIC-STROKE: Asundexian Lowers Recurrent Stroke Risk in Patients With Noncardioembolic Stroke or TIA - American College of Cardiology
18. The “cardiometabolic index” as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus - ScienceDirect
19. Association of cardiometabolic index and risk of stroke: A systematic review and meta-analysis - ScienceDirect
20. Association between cardiometabolic index and stroke risk: insights from the CHARLS cohort study
21. Long-Term Risk of Stroke After Transient Ischemic Attack or Minor Stroke
22. Residual Risk of Recurrent Stroke Despite Anticoagulation in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis | Cerebrovascular Disease | JAMA Neurology | JAMA Network